✉news ScienceBiology first seen 1 d ago, last 4 h ago, peak #1
The Regulatory Bottleneck in Aging Biology
The Lifespan Research Institute is highlighting what it calls the regulatory bottleneck in aging biology, arguing that approval pathways designed for single-disease drugs are poorly suited to therapies targeting aging itself. The piece has drawn attention among researchers and advocates who say slow, mismatched regulation is delaying gero-protective treatments from reaching clinical trials and patients.
Why now: Growing interest in longevity therapies is putting pressure on regulators to adapt frameworks not built for aging-targeted interventions.
Lifespan Research Instituteaging biologyFDA
Rank over time, top of the chart is #1. 17 snapshots from 1 d ago to 4 h ago.
Evidence
- The Regulatory Bottleneck in Aging Biology · Lifespan Research Institute
API: https://socialmediatrends-api.osmike.com/v1/trends/3764204